Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17303476 | 0.85 | NOTUM (0.58) | TP53NOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL321724 | 0.84 | LMNA (0.61) | TP53NOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL611583 | 0.82 | NOTUM (0.55) | TP53NOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL323044 | 0.82 | NOTUM (0.55) | TP53NOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL1019716 | 0.82 | NOTUM (0.59) | TP53NOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL62700 | 0.81 | MAPT (0.72) | TP53NOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL16220632 | 0.81 | KAT6A (0.54) | TP53NOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL20646989 | 0.81 | KDM4E (0.50) | TP53NOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL13687628 | 0.81 | HRH3 (0.50) | TP53NOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL2401139 | 0.81 | NOTUM (0.53) | TP53NOTUMKDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710249-A | Preparation method of polysubstituted isoquinoline and 1, 6-naphthyridine compound and common molecular framework of photoelectric material | 广东工业大学 | 2023-02-24 | — | — | CN | claimed |
| EP-4477271-B1 | N-(PHENYL)-5-(HETEROARYL)-1H-PYRAZOL-3-AMINE DERIVATIVES AS TNIK INHIBITORS FOR USE IN THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2026-05-13 | — | — | EP | disclosed |
| CN-119930469-A | Chalcone compound containing alpha, beta-unsaturated hydroxamic acid groups and preparation method and application thereof | 河北医科大学 | 2025-05-06 | — | — | CN | disclosed |
| EP-4477271-A2 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-12-18 | — | — | EP | disclosed |
| CN-115710249-B | Preparation method of polysubstituted isoquinoline and 1, 6-naphthyridine compound and common molecular skeleton of photoelectric material | 广东工业大学 | 2024-11-19 | — | — | CN | disclosed |
| EP-3749648-B1 | N-(PHENYL)-5-(PHENYL)-1H-PYRAZOL-3-AMINE DERIVATIVES AS TNIK INHIBITORS FOR USE IN THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2024-10-30 | — | — | EP | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-111836801-B | Compounds for inhibiting TNIK and medical use thereof | 韩国化学硏究院 | 2024-02-02 | — | — | CN | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | SENOMYX, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-2091937-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-2043970-A2 | IRON-COPPER CO-CATALYZED PROCESS FOR CARBON-CARBON OR CARBON-HETEROATOM BONDING | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008051406-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-7339005-B2 | Process for producing modified diene polymer rubber | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-04 | — | — | US | disclosed |
| WO-2008004088-A2 | IRON-COPPER CO-CATALYZED PROCESS FOR CARBON-CARBON OR CARBON-HETEROATOM BONDING | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004088-A2 | IRON-COPPER CO-CATALYZED PROCESS FOR CARBON-CARBON OR CARBON-HETEROATOM BONDING | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-10 | — | — | WO | disclosed |
| US-20040152845-A1 | Process for producing modified diene polymer rubber | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | TAS2R10, TAS2R41, TAS2R30 | TP53 1197/4885NOTUM 362/4885KDM4E 2993/4885 |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | TP53 1726/4885NOTUM 2658/4885KDM4E 4071/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | TP53 503/4885NOTUM 4073/4885KDM4E 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.